Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome

El-Salhy,Magdy; Wendelbo,Ingvild   Haukaas; Gundersen,Doris

doi:10.3892/mmr.2013.1325

Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome

Authors:
- Magdy El-Salhy
- Ingvild Haukaas Wendelbo
- Doris Gundersen
View Affiliations

Affiliations: Section for Gastroenterology, Department of Medicine, Stord Helse-Fonna Hospital, Stord, Norway, Section for Gastroenterology, Institute of Medicine, University of Bergen, Bergen, Norway, Department of Research, Helse-Fonna, Haugesund, Norway
Published online on: February 19, 2013 https://doi.org/10.3892/mmr.2013.1325
Pages: 1241-1244
Copyright: © El-Salhy et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Irritable bowel syndrome (IBS) is a common disorder that considerably reduces the quality of life and productivity of patients. Chromogranin A (CgA) is a common marker for endocrine cells. CgA cell density has been reported to be reduced in the duodenum and colon of IBS patients. This study was undertaken to investigate CgA cell density in the ileum of these patients. The study involved 98 patients with IBS, according to the Rome III Criteria (77 females and 21 males, with an average age of 35 years). In total, 35 patients had diarrhoea-predominant symptoms (IBS-D), 32 had constipation-predominant symptoms (IBS-C), and 31 had a mixture of both diarrhoea and constipation (IBS-M). In this study, 27 subjects were used as controls (16 females and 11 males, with an average age of 52 years). Colonoscopies were performed on the patients and controls and biopsies were obtained from the ileum. Sections were immunostained with the avidin-biotin complex (ABC) for CgA and quantified using computerized image analysis. The CgA density in the controls was 63.2±4.4 (mean ± SEM), for all IBS patients it was 28.6±2.1, for IBS-D it was 28.8±3.4, for IBS-M it was 26.5±3.9 and for IBS-C it was 30.3±3.7. There was a statistically significant difference between the controls and all IBS patients (IBS-D, IBS-M and IBS-C; P<0.0001 for all). The present study showed that CgA cell density in the ileum of IBS patients was reduced, regardless of subtype. Thus, it appears that there is endocrine cell depletion in both the small and large intestine of IBS patients, whereas IBS is normally considered to be a functional condition without any detectable abnormalities. The present finding lends support to the suggestion that IBS is caused by a biological abnormality, and intestinal CgA cell density may be used as a biological marker for the diagnosis of IBS.

View Figures

View References

1	El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: Irritable Bowel Syndrome: Diagnosis, Pathogenesis & Treatment Options. Nova Science Publishers Inc; New York, NY: 2012
2	Thompson WG: A world view of IBS. Irritable Bowel Syndrome: Diagnosis and Treatment. Camilleri M and Spiller R: Saunders; Philadelphia and London: pp. 17–26. 2002
3	Drossman DA, Li Z, Andruzzi E, et al: U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 38:1569–1580. 1993. View Article : Google Scholar : PubMed/NCBI
4	Hungin AP, Whorwell PJ, Tack J and Mearin F: The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 17:643–650. 2003. View Article : Google Scholar : PubMed/NCBI
5	Wilson S, Roberts L, Roalfe A, Bridge P and Singh S: Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 54:495–502. 2004.PubMed/NCBI
6	Whitehead WE, Burnett CK, Cook EW III and Taub E: Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 41:2248–2253. 1996. View Article : Google Scholar : PubMed/NCBI
7	Everhart JE and Renault PF: Irritable bowel syndrome in office-based practice in the United States. Gastroenterology. 100:998–1005. 1991.PubMed/NCBI
8	Harvey RF, Salih SY and Read AE: Organic and functional disorders in 2000 gastroenterology outpatients. Lancet. 1:632–634. 1983. View Article : Google Scholar : PubMed/NCBI
9	Taupenot L, Harper KL and O’Connor DT: The chromogranin-secretogranin family. N Engl J Med. 348:1134–1149. 2003. View Article : Google Scholar : PubMed/NCBI
10	Wiedenmann B and Huttner WB: Synaptophysin and chromogranins/secretogranins – widespread constituents of distinct types of neuroendocrine vesicales and new tools in tumor diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol. 58:95–121. 1989.
11	El-Salhy M, Lillebø E, Reinemo A and Salmelid L: Ghrelin in patients with irritable bowel syndrome. Int J Mol Med. 23:703–707. 2009. View Article : Google Scholar : PubMed/NCBI
12	Sjölund K, Ekman R and Wierup N: Covariation of plasma ghrelin and motilin in irritable bowel syndrome. Peptides. 31:1109–1112. 2010.PubMed/NCBI
13	Dizdar V, Spiller R, Singh G, Hanevik K, Gilja OH, El-Salhy M and Hausken T: Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 31:883–891. 2010.PubMed/NCBI
14	El-Salhy M, Vaali K, Dizdar V and Hausken T: Abnormal small intestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci. 55:3508–3513. 2010. View Article : Google Scholar : PubMed/NCBI
15	El-Salhy M, Gundersen D, Ostgaard H, Lomholt-Beck B, Hatlebakk JG and Hausken T: Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci. 57:873–878. 2012. View Article : Google Scholar : PubMed/NCBI
16	El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Submitted. 2012.
17	El-Salhy M, Seim I, Chopin L, Gundersen D, Hatlebakk JG and Hausken T: Irritable bowel syndrome: the role of gut neuroendocrine peptides. Front Biosci (Elite Ed). 4:2783–2800. 2012. View Article : Google Scholar : PubMed/NCBI
18	Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM and Moses PL: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 126:1657–1664. 2004. View Article : Google Scholar : PubMed/NCBI
19	Wang SH, Dong L, Luo JY, Gong J, Li L, Lu XL and Han SP: Decreased expression of serotonin in the jejenum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol. 13:6041–6047. 2007. View Article : Google Scholar : PubMed/NCBI
20	Park JH, Rhee PL, Kim G, Lee JH, Kim YH, Kim JJ, Rhee JC and Song SY: Enteroendocrine cell counts correlated with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 18:539–546. 2006. View Article : Google Scholar : PubMed/NCBI
21	Dunlop SP, Jenkins D and Spiller RC: Distinctive clinical, psychological and histological feature of postinfective irritable bowel syndrome. Am J Gastroenterol. 98:1578–1583. 2003. View Article : Google Scholar : PubMed/NCBI
22	Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK and Cho SW: The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 23:1689–1694. 2008. View Article : Google Scholar : PubMed/NCBI
23	Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M and Neal KR: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 47:804–811. 2000. View Article : Google Scholar
24	Kim HS, Lim JH, Park H and Lee SI: Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection – an observation in small case control study. Yonsei Med J. 51:45–51. 2010.PubMed/NCBI
25	Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA and Spiller RC: Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 3:349–357. 2005. View Article : Google Scholar : PubMed/NCBI
26	Deftos LJ: Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev. 12:181–187. 1991. View Article : Google Scholar : PubMed/NCBI
27	El-Salhy M, Lomholt-Beck B and Hausken T: Chromogranin as a tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol. 45:1435–1439. 2010. View Article : Google Scholar
28	El-Salhy M, Mazzawi T, Gundersen D and Hausken T: Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. Mol Med Rep. 6:1223–1225. 2012.PubMed/NCBI
29	Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F and Spiller RC: Functional bowel disorder. Gastroenterology. 130:1480–1491. 2006. View Article : Google Scholar : PubMed/NCBI
30	Sandström O and El-Salhy M: Aging and endocrine cells of human duodenum. Mech Ageing Dev. 108:39–48. 1999.
31	Sandström O and El-Salhy M: Human rectal endocrine cells and aging. Mech Ageing Dev. 108:219–226. 1999.PubMed/NCBI